The estimated Net Worth of Robert Hershberg is at least 217 千$ dollars as of 2 February 2023. Robert Hershberg owns over 53,000 units of Nanostring Technologies Inc stock worth over 6,444$ and over the last 10 years he sold NSTG stock worth over 15,288$. In addition, he makes 194,979$ as Independent Director at Nanostring Technologies Inc.
Robert has made over 31 trades of the Nanostring Technologies Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 53,000 units of NSTG stock worth 23,850$ on 2 February 2023.
The largest trade he's ever made was exercising 53,000 units of Nanostring Technologies Inc stock on 2 February 2023 worth over 23,850$. On average, Robert trades about 3,375 units every 21 days since 2015. As of 2 February 2023 he still owns at least 61,193 units of Nanostring Technologies Inc stock.
You can see the complete history of Robert Hershberg stock trades at the bottom of the page.
Dr. Robert M. Hershberg M.D. Ph.D. serves as Independent Director of the Company. Dr. Hershberg, has been a Venture Partner at Frazier Healthcare Partners, a venture capital firm focused exclusively on biotechnology investments. From March 2017 until the acquisition of Celgene by Bristol-Myers Squibb in November 2019, Dr. Hershberg served as Executive Vice President of Business Development and Global Alliances of Celgene Corporation, a publicly-traded biopharmaceutical company, where he was a member of the Executive Committee and was responsible for all business development related activities across the company and management of business alliances. From January 2016 to March 2017, Dr. Hershberg served as the Chief Scientific Officer, where he was responsible for overseeing Celgene’s scientific platforms, discovery capabilities and early clinical development, and from July 2014 to January 2016, he served as Senior Vice-President of Immuno-Oncology at Celgene, where he led Celgene’s research and early development efforts across its immuno-oncology portfolio. From 2011 to 2017, Dr. Hershberg was President and Chief Executive Officer of VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company, which he co-founded in 2006; from 2006 to 2011 he also served as its Executive Vice President and Chief Medical Officer. Prior to co-founding VentiRx, Dr. Hershberg served as Senior Vice President and Chief Medical Officer at Dendreon Corporation, a biotechnology company, where he led the clinical, regulatory and biometrics groups, focusing on the development of Provenge® in metastatic prostate cancer. From 2001 to 2003, Dr. Hershberg was the Vice President of Medical Genetics at Corixa, a pharmaceutical company (acquired by GlaxoSmithKline in 2005). Earlier in his career, Dr. Hershberg served as an Assistant Professor at Harvard Medical School and an Associate Physician at the Brigham and Women’s Hospital in Boston, Massachusetts. Dr. Hershberg holds a clinical faculty position at the University of Washington School
As the Independent Director of Nanostring Technologies Inc, the total compensation of Robert Hershberg at Nanostring Technologies Inc is 194,979$. There are 16 executives at Nanostring Technologies Inc getting paid more, with R. Bradley Gray having the highest compensation of 7,288,840$.
Robert Hershberg is 57, he's been the Independent Director of Nanostring Technologies Inc since 2015. There are 11 older and 7 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.
Robert's mailing address filed with the SEC is C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE, WA, 98109.
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over 114,083,977$ worth of Nanostring Technologies Inc stock and bought 981,722 units worth 9,126,410$ . The most active insiders traders include Charles P Jr Waite、Lifesciences Ii, L.P.Clarus...、Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of 4,371$. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth 15,569$.
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
Nanostring Technologies Inc executives and other stock owners filed with the SEC include: